<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451734</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1306900</org_study_id>
    <nct_id>NCT03451734</nct_id>
  </id_info>
  <brief_title>Individualized Optimal Therapy of Antipsychotics</brief_title>
  <official_title>Individualized Optimal Therapy of Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Nanjing Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Mental Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to establish and improve the Chinese schizophrenia clinical
      information database and biobank patients, by evaluating the related genetic gene,
      psychopathology, neuropsychology, brain physiology and biochemistry the image indexes, and
      found 6 kinds of commonly used antipsychotics (olanzapine, risperidone, aripiprazole,
      ziprasidone, amisulpride, haloperidol) treatment response biomarkers and biomarker selection
      which can predict antipsychotic efficacy and adverse reactions of schizophrenia, establish
      individual clinical disease commonly used antipsychotic drug treatment to optimal treatment
      for the disease, and further testing, validation and evaluation of biomarkers in clinical
      independent samples. At the same time, the investigator focus on solving the problem of
      antipsychotic induced metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a serious mental disease that threaten human health, the lifetime prevalence
      rate of about 1%, the current Chinese schizophrenia patients nearly 10 million people,
      antipsychotic drugs is the main method in the treatment of schizophrenia, but the efficacy
      and safety of individual differences, about 1/3 in drug treatment of patients with no adverse
      reaction, patients with different drug reactions (such as extrapyramidal symptom(EPS),
      metabolic syndrome) with different susceptibility. The investigators aim to set up an
      objective and reliable biological indicator system that accurately predicts the response of
      antipsychotic drugs, and effective strategies to prevent metabolic syndrome caused by
      psychotropic drugs. The aim of this project is to establish individualized evaluation system
      for different kinds of schizophrenia commonly used antipsychotic drugs, and to build an
      optimized treatment plan that accords with individualized clinical indications, and to focus
      on solving the metabolic syndrome caused by antipsychotics. The research content closely
      guide, relying on the National Center of clinical medicine research and clinical alliance
      resources, many domain experts combined with basic research, clinical research and
      technology, establish and improve the schizophrenia clinical information database and biobank
      patients, by evaluating the related genetic gene, psychopathology, neuropsychology, brain
      physiology and biochemistry the image indexes, and found 6 kinds of commonly used
      antipsychotics (olanzapine, risperidone, aripiprazole, ziprasidone, amisulpride, haloperidol)
      treatment response biomarkers and biomarker selection can predict antipsychotic efficacy and
      adverse reactions of schizophrenia, establish individual clinical disease commonly used
      antipsychotic drug treatment to optimal treatment for the disease, and further testing,
      validation and evaluation of biomarkers in clinical independent samples In order to promote
      the development of individualized treatment of antipsychotic drugs and improve the level of
      treatment, the investigators set up an optimized treatment plan based on the psychopathology
      neuropsychological, image, genetic, physiological and biochemical models, which is suitable
      for individualized clinical indications. At the same time the needle syndrome is a serious
      threat to the health of adverse reactions in patients with antipsychotic medication induced
      metabolic syndrome, comprehensive intervention therapy and lifestyle intervention to
      construct the combination strategy, focused on solving the problem of antipsychotic induced
      metabolic syndrome and its treatment due to poor compliance, the schizophrenia clinical
      treatment compliance 5% above
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Weeks</target_duration>
  <primary_outcome>
    <measure>Positive And Negative Syndrome Scale (PANSS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of Positive And Negative Syndrome Scale (PANSS) total, positive and negative symptoms before and after treatment at different follow up point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions(CGI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of Clinical Global Impressions(CGI):severity of illness(SI), global improvement(GI) and efficacy index(EI) before and after treatment at different follow up point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Assessment Function(GAF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of Global Assessment Function(GAF) before and after treatment at different follow up point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MATRICS Consensus Cognitive Battery (MCCB) composite score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure before and after treatment at different follow up point.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Efficacy</condition>
  <condition>Adverse Drug Effect of Antipsychotics and Neuroleptics</condition>
  <condition>Individualed Opitmal Therapy</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Antipsychotic drugs</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Antipsychotic drugs</description>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Antipsychotic drugs</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Antipsychotic drugs</description>
    <arm_group_label>Ziprasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>Antipsychotic drugs</description>
    <arm_group_label>Amisulpride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Antipsychotic drugs</description>
    <arm_group_label>Haloperidol</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood,serum.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Meet the Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for
        schizophrenia;Duration of illness less than 3 years with current symptoms exacerbation;Male
        and female with aged 17 to 65 years;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for
             schizophrenia;

          2. Duration of illness less than 3 years with current symptoms exacerbation;

          3. Male and female with aged 17 to 65 years;

          4. Signed the study consent for participation

        Exclusion Criteria:

          1. Having history of substance dependence or abuse or whose symptoms are caused by the
             other diagnosable mental disorders;

          2. Having history of traumatic brain injury, seizures or other known neurological or
             organic diseases of the central nervous system;

          3. Taking antidepressants, stimulants, mood stabilizer or accepts electricity shock
             treatment;

          4. Having current suicidal or homicidal thoughts or any safety concern by research staff
             that cannot be manage in an inpatient setting;

          5. The routine blood tests showing abnormal renal, liver function;

          6. Pregnant or lactating women.

          7. No administration of any antibiotics in a mouth
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>renrong wu, Ph.D</last_name>
    <phone>+8615874179855</phone>
    <email>wurenrong2013@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ying wang, Bachelor</last_name>
    <phone>+8613667343454</phone>
    <email>13667343454@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mental Health Institute of 2nd Xiangya Hospital,CSU</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renrong Wu, PhD</last_name>
      <phone>15874179855</phone>
      <email>wurenrong2013@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Renrong Wu</investigator_full_name>
    <investigator_title>M.D,Ph.D,Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Sultopride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

